What question did this study set out to answer?

This review aims to summarize the effectiveness and safety of systemic therapies for advanced basal cell carcinoma (aBCC).

Transforming Outcomes in Advanced Basal Cell Carcinoma: The Evolving Role of Systemic Therapy

View Full Paper

Ask AI

Bookmark

Authors

Comprehensive review discusses systemic treatments and their outcomes in advanced basal cell carcinoma, highlighting potential improvements.

This review aims to summarize the effectiveness and safety of systemic therapies for advanced basal cell carcinoma (aBCC).
Review of clinical evidence on systemic treatments for aBCC.
Analysis of efficacy, safety, and resistance mechanisms of hedgehog pathway inhibitors and immune checkpoint inhibitors.
Discussion of ongoing research on therapeutic strategies and combination therapies.
First-line HHIs, vismodegib and sonidegib, show effective disease control and function preservation in complex cases.
Second-line immune checkpoint inhibition provides durable responses in selected aBCC patients, but with associated adverse events.
Research is focused on enhancing long-term disease control through alternative dosing, combination therapies, and predictive biomarkers.

Patsea et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Comprehensive review discusses systemic treatments and their outcomes in advanced basal cell carcinoma, highlighting potential improvements.